MedicineChemistry

Matt J. Petrus, A. Peier, M. Bandell, S. Hwang, T. Huynh, N. Olney, T. Jegla, Ardem Patapoutian

2007.1.1Molecular Pain

DOI: 10.1186/1744-8069-3-40

tlooto Summary

A specific small molecule TRPA1 inhibitor (AP18) is developed that can reduce cinnameldehyde-induced nociception in vivo and is capable of reversing CFA-induced mechanical hyperalgesia in mice.

Abstract

Mechanical hyperalgesia is a clinically-relevant form of pain sensitization that develops through largely unknown mechanisms. TRPA1, a Transient Receptor Potential ion channel, is a sensor of pungent chemicals that may play a role in acute noxious mechanosensation and cold thermosensation. We have developed a specific small molecule TRPA1 inhibitor (AP18) that can reduce cinnameldehyde-induced nociception in vivo. Interestingly, AP18 is capable of reversing CFA-induced mechanical hyperalgesia in mice. Although TRPA1-deficient mice develop normal CFA-induced hyperalgeisa, AP18 is ineffective in the knockout mice, consistent with an on-target mechanism. Therefore, TRPA1 plays a role in sensitization of nociception, and that compensation in TRPA1-deficient mice masks this requirement.

Citation format

PETRUS, Matt J., et al. A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Molecular Pain, 2007, 3: 40–40.